Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
Colorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neopla...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/10/1491 |
id |
doaj-de889b8ed23f432fa256f95eb5e67455 |
---|---|
record_format |
Article |
spelling |
doaj-de889b8ed23f432fa256f95eb5e674552020-11-25T02:16:00ZengMDPI AGCancers2072-66942019-10-011110149110.3390/cancers11101491cancers11101491Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic CellsSandra Gessani0Filippo Belardelli1Center for Gender-Specific Medicine, Istituto Superiore di Sanità, 00161 Rome, ItalyInstitute of Translational Pharmacology, CNR, 00131 Rome, ItalyColorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neoplastic cells, including immune cells. Several immune dysfunctions were described in CRC patients at different disease stages. Many studies underline the role of microbiota, obesity-related inflammation, diet and host reactive cells, including dendritic cells (DC), in CRC pathogenesis. Here, we focused on DC, the main cells linking innate and adaptive anti-cancer immunity. Variations in the number and phenotype of circulating and tumor-infiltrating DC have been found in CRC patients and correlated with disease stages and progression. A critical review of DC-based clinical studies and of recent advances in cancer immunotherapy leads to consider new strategies for combining DC vaccination strategies with check-point inhibitors, thus opening perspectives for a more effective management of this neoplastic disease.https://www.mdpi.com/2072-6694/11/10/1491colorectal cancerdendritic cellsimmunotherapypathogenesisrisk factors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sandra Gessani Filippo Belardelli |
spellingShingle |
Sandra Gessani Filippo Belardelli Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells Cancers colorectal cancer dendritic cells immunotherapy pathogenesis risk factors |
author_facet |
Sandra Gessani Filippo Belardelli |
author_sort |
Sandra Gessani |
title |
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells |
title_short |
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells |
title_full |
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells |
title_fullStr |
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells |
title_full_unstemmed |
Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells |
title_sort |
immune dysfunctions and immunotherapy in colorectal cancer: the role of dendritic cells |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2019-10-01 |
description |
Colorectal cancer (CRC), a multi-step malignancy showing increasing incidence in today’s societies, represents an important worldwide health issue. Exogenous factors, such as lifestyle, diet, nutrition, environment and microbiota, contribute to CRC pathogenesis, also influencing non neoplastic cells, including immune cells. Several immune dysfunctions were described in CRC patients at different disease stages. Many studies underline the role of microbiota, obesity-related inflammation, diet and host reactive cells, including dendritic cells (DC), in CRC pathogenesis. Here, we focused on DC, the main cells linking innate and adaptive anti-cancer immunity. Variations in the number and phenotype of circulating and tumor-infiltrating DC have been found in CRC patients and correlated with disease stages and progression. A critical review of DC-based clinical studies and of recent advances in cancer immunotherapy leads to consider new strategies for combining DC vaccination strategies with check-point inhibitors, thus opening perspectives for a more effective management of this neoplastic disease. |
topic |
colorectal cancer dendritic cells immunotherapy pathogenesis risk factors |
url |
https://www.mdpi.com/2072-6694/11/10/1491 |
work_keys_str_mv |
AT sandragessani immunedysfunctionsandimmunotherapyincolorectalcancertheroleofdendriticcells AT filippobelardelli immunedysfunctionsandimmunotherapyincolorectalcancertheroleofdendriticcells |
_version_ |
1724893434699841536 |